Systemwide Enhancements Deliver Exceptional Configurability, Performance and Efficiency
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is proud to announce the latest release of iMedNet™ eClinical, its innovative, cloud-based technology platform. iMedNet provides an extremely intuitive, flexible and affordable software-as-a-service (SaaS) solution – ideal for clinical trial sponsors and CROs wishing to quickly and efficiently build studies themselves.
"This iMedNet release delivers significant new and enhanced functionality throughout the system, encompassing our easy-to-use forms designer and randomization modules, as well as our casebook manager and robust reporting toolsets," remarked M. Clareece West, Chief Operating Officer of MedNet Solutions. "At MedNet, we're dedicated to continually refining our eClinical technologies to ensure we always deliver fully compliant and validated best-in-class solutions. Our most recent iMedNet release is tangible proof of that promise to our customers."
"We're incredibly excited about the latest iMedNet release," stated John M. (Rob) Robertson, President and CEO of MedNet Solutions. "It takes our iMedNet platform to the next level in terms of convenience, speed and control, not only for our customers, but for everyone involved in the clinical research initiative. And we're not stopping there; we're working on more exciting new functionality that will be rolled out early this coming summer. Stay tuned."
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.